[On the current debate on lowering LDL cholesterol with ezetimibe].
Helmut
H
Schunn
D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use*; D000069059:Atorvastatin; D001384:Azetidines / Q000191:economics* / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood*; D003362:Cost-Benefit Analysis; D004338:Drug Combinations; D016527:Drug Costs / Q000706:statistics & numerical data*; D000069438:Ezetimibe; D000069499:Ezetimibe, Simvastatin Drug Combination; D005382:Financing, Personal / Q000191:economics; D005464:Fluorobenzenes / Q000191:economics / Q000627:therapeutic use; D005858:Germany; D006538:Heptanoic Acids / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000191:economics* / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000191:economics*; D009313:National Health Programs / Q000191:economics*; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use; D011758:Pyrroles / Q000191:economics / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D055502:Secondary Prevention; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D019821:Simvastatin; D006903:Hydroxymethylglutaryl CoA Reductases; D000069438:Ezetimibe